AJP - GI Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Gastrointest Liver Physiol 278: G266-G272, 2000;
0193-1857/00 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Jong, T. A.
Right arrow Articles by O'Brien, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Jong, T. A.
Right arrow Articles by O'Brien, P. E.
Vol. 278, Issue 2, G266-G272, February 2000

Inhibition of rat colon tumors by sulindac and sulindac sulfone is independent of K-ras (codon 12) mutation

Tanya A. de Jong1, Stewart A. Skinner1, Cathy Malcontenti-Wilson1, Daphne Vogiagis1, Michael Bailey2, Ian R. van Driel3, and Paul E. O'Brien1

1 Department of Surgery, 2 Department of Epidemiology and Preventive Medicine, and 3 Department of Pathology and Immunology, Monash University Medical School, Prahran, Melbourne 3181, Australia

Nonsteroidal anti-inflammatory drug (NSAID) use reduces the risk of colorectal cancer by 40-50%. Previous studies suggest that effective inhibition of colorectal cancer by NSAIDs may be dependent on the presence or absence of a K-ras mutation. This study was aimed at determining the relationship between inhibition of colorectal cancer by sulindac and sulindac sulfone and the presence of activating K-ras mutations in the 1,2-dimethylhydrazine dihydrochloride rat model. Sulindac (20 mg · kg-1 · day-1), sulindac sulfone (40 mg · kg-1 · day-1), or vehicle was administered orally to male Sprague-Dawley rats for a 4-wk period beginning 20 wk after tumor induction. Tumor number and volume were measured before treatment by laparotomy and colonoscopy and again after treatment. Sulindac and sulindac sulfone treatment significantly reduced the number and volume of colorectal tumors compared with control rats. For K-ras (codon 12) mutation detection, frozen tumor tissue was collected at the endpoint. We found K-ras codon 12 mutations in 11 of 21 (52%) control tumors. The proportion of tumors with K-ras mutations in the sulindac-treated group [5 of 8 (62%); odds ratio = 1.51 (95% confidence interval = 0.29, 8.33)] and the proportion of sulindac sulfone-treated tumors [9 of 14 (64%); odds ratio = 1.63 (95% confidence interval = 0.41, 6.66)] were not significantly different from controls. Tumor inhibition did not correlate with K-ras (codon 12) mutation status, which suggests that the mechanism of inhibition of rat colorectal cancer by sulindac and sulindac sulfone is independent of K-ras mutation.

colorectal cancer; 1,2-dimethylhydrazine dihydrochloride, nonsteroidal anti-inflammatory drugs


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
Y. Wen, S. F. Giardina, D. Hamming, J. Greenman, E. Zachariah, M. D. Bacolod, H. Liu, J. Shia, P. S. Amenta, F. Barany, et al.
GRO{alpha} Is Highly Expressed in Adenocarcinoma of the Colon and Down-Regulates Fibulin-1.
Clin. Cancer Res., October 15, 2006; 12(20): 5951 - 5959.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
L. Moragoda, R. Jaszewski, P. Kulkarni, and A. P. N. Majumdar
Age-associated loss of heterozygosity of tumor suppressor genes in the gastric mucosa of humans
Am J Physiol Gastrointest Liver Physiol, June 1, 2002; 282(6): G932 - G936.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. Vogiagis, W. Brown, E. M. Glare, and P. E. O'Brien
Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels
Carcinogenesis, June 1, 2001; 22(6): 869 - 874.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online